Every 10-Q that Metagenomi Therapeutics, Inc (MGX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGX filings page.
Metagenomi Therapeutics, Inc. reported continued operating losses as it advances its in vivo genome-editing pipeline and Ionis collaboration. For the quarter ended June 30, 2026, collaboration revenue was a negative $0.3 million, down from $8.5 million a year earlier, largely due to an April 2026 modification of the Ionis agreement that triggered a $2.6 million negative cumulative catch-up adjustment and lower current-period activity.
Quarterly research and development expense was $22.5 million and general and administrative expense was $6.0 million, together slightly below the prior year as the company reprioritized programs while increasing external R&D services. Net loss for the quarter widened to $27.5 million, and the six‑month net loss reached $50.5 million, or $1.34 per share basic and diluted.
As of June 30, 2026, Metagenomi held $39.0 million in cash and cash equivalents and $81.6 million in available-for-sale marketable securities, for $120.7 million of liquidity, plus $4.4 million of restricted cash. Management believes these resources are sufficient to fund the current operating plan for at least 12 months and notes an unused $75.0 million at-the-market equity program. Deferred revenue of $11.2 million reflects remaining obligations under the Ionis collaboration.
Metagenomi, Inc. (MGX) reported Q3 2025 results. Collaboration revenue was $8.7 million, down from $11.5 million a year ago, while operating expenses declined to $31.5 million from $33.9 million. Net loss was $20.4 million versus $18.8 million last year, or $0.55 per share.
Cash and cash equivalents were $32.8 million and available-for-sale marketable securities were $151.3 million as of September 30, 2025, supporting management’s view that liquidity is sufficient for at least the next 12 months. Deferred revenue totaled $14.8 million, reflecting ongoing recognition under the Ionis collaboration.
The company terminated the Affini‑T agreement following Affini‑T’s assignment for the benefit of creditors and marked its Affini‑T investment to zero. Metagenomi also signed a non‑exclusive LNP license with Acuitas, recording a $3.0 million upfront licensing fee in research and development expense. Under the Ionis agreement, the company recognized $8.5 million of collaboration revenue in Q3 and reported $20.0 million remaining performance obligations to be recognized over future periods. Shares outstanding were 37,546,751 as of September 30, 2025.
Metagenomi, Inc. reported interim results showing continued R&D spending and collaboration revenue while maintaining a multi-month cash runway. Total assets decreased to $272.3 million from $324.6 million, driven primarily by lower available-for-sale marketable securities of $178.1 million versus $220.9 million at year-end. Cash and cash equivalents were $26.9 million and, together with marketable securities, management states approximately $205.0 million of liquidity is available to fund operations for at least the next 12 months.
Collaboration revenue for the quarter was $8.5 million, primarily from Ionis, while operating expenses totaled $29.5 million for the quarter with R&D at $22.5 million. Net loss was $19.9 million for the quarter and $44.9 million for the six months, widening year-over-year. The company recognized a $1.3 million fair value loss on its long-term investment in Affini-T, which it valued at $0.0 million at June 30, 2025. Deferred revenue related to Ionis remains material at $22.4 million. A securities class action filed in September 2024 is pending and the company filed a motion to dismiss in May 2025.